EP4698531A1 - Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques - Google Patents

Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques

Info

Publication number
EP4698531A1
EP4698531A1 EP24718537.4A EP24718537A EP4698531A1 EP 4698531 A1 EP4698531 A1 EP 4698531A1 EP 24718537 A EP24718537 A EP 24718537A EP 4698531 A1 EP4698531 A1 EP 4698531A1
Authority
EP
European Patent Office
Prior art keywords
pyrrolo
piperidyl
pyrazin
phenyl
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24718537.4A
Other languages
German (de)
English (en)
Inventor
Franck Slowinski
Jidong Zhang
Amélie Dommergue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP4698531A1 publication Critical patent/EP4698531A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés qui peuvent inhiber ERK5. L'invention concerne également des compositions pharmaceutiques et des utilisations médicales de celles-ci, y comrpis une utilisation dans le traitement ou la prévention d'affections telles que des cancers.
EP24718537.4A 2023-04-19 2024-04-18 Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques Pending EP4698531A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23315084 2023-04-19
PCT/EP2024/060592 WO2024218235A1 (fr) 2023-04-19 2024-04-18 Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques

Publications (1)

Publication Number Publication Date
EP4698531A1 true EP4698531A1 (fr) 2026-02-25

Family

ID=86387401

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24718537.4A Pending EP4698531A1 (fr) 2023-04-19 2024-04-18 Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques

Country Status (3)

Country Link
EP (1) EP4698531A1 (fr)
CN (1) CN121002026A (fr)
WO (1) WO2024218235A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US20050288299A1 (en) 2002-10-09 2005-12-29 Mavunkel Babu J Azaindole derivatives as inhibitors of p38 kinase
WO2019170543A1 (fr) 2018-03-07 2019-09-12 Bayer Aktiengesellschaft Identification et utilisation d'inhibiteurs d'erk5
WO2021195781A1 (fr) 2020-04-01 2021-10-07 Repare Therapeutics Inc. Composés, compositions pharmaceutiques et procédés de préparation et d'utilisation associés
WO2022051569A1 (fr) * 2020-09-04 2022-03-10 Ikena Oncology, Inc. 3-pipéridinyl-pyrrolo[2,3-b]pyridines substituées et composés apparentés et leur utilisation dans le traitement d'états médicaux

Also Published As

Publication number Publication date
CN121002026A (zh) 2025-11-21
WO2024218235A1 (fr) 2024-10-24

Similar Documents

Publication Publication Date Title
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
KR20230019462A (ko) 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
BR112016012262B1 (pt) Acrilamidas heterocíclicas farmaceuticamente ativas e composições para tratar e prevenir condições mediadas por jac
EA036013B1 (ru) Новые спиро[3h-индол-3,2'-пирролидин]-2(1h)-оновые соединения и производные в качестве ингибиторов mdm2-p53
EA027533B1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
JP7365332B2 (ja) Ｃｄｋ８／１９阻害薬としての新規ヘテロ環式化合物
EP2943485A1 (fr) Composés de carboxamide aromatique bicyclique utiles comme inhibiteurs de pim kinase
EP3024833A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US11034696B2 (en) Compounds for inhibiting LRRK2 kinase activity
KR102667331B1 (ko) 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도
JP2020504139A (ja) キナーゼ阻害剤としての置換された縮合ヘテロアリール化合物及びその用途
CN116583285B (zh) N-(咪唑并[1,2-b]哒嗪-3-基)-1-环己基-2H-吲唑-5-甲酰胺和N-(吡唑并[1,5-a]嘧啶-3-基)-1-环己基-2H-吲唑-5-甲酰胺衍生物作为IRAK4抑制剂用于治疗哮喘
WO2024044570A1 (fr) Composés et procédés de modulation de her2
US20230348462A1 (en) Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
TW202317106A (zh) 作為egfr抑制劑之取代胺基吡啶化合物
JP6280130B2 (ja) キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
WO2024218235A1 (fr) Composés de pyrrolopyrazine, leur préparation et leurs utilisations thérapeutiques
WO2023209090A1 (fr) Composés hétéroaromatiques bicycliques et leur application dans le traitement du cancer
JP2026514814A (ja) ピロロピラジン化合物、その調製物及びその治療的使用
US12258327B2 (en) 5-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors
WO2026087618A1 (fr) Composés d'imidazo[1,2-b]pyridazine, leur préparation et leurs utilisations thérapeutiques
WO2025153712A1 (fr) Composés tricycliques, leur préparation et leurs utilisations thérapeutiques en tant qu'inhibiteurs de erk5
RU2739489C2 (ru) Новые гетероциклические соединения как ингибиторы CDK8/19
WO2026087613A1 (fr) Composés de 3-aza-bicyclo[3.3.0]octane, leur préparation et leurs utilisations thérapeutiques
WO2024223905A1 (fr) Composés de pyridoimidazolone, leur préparation et leurs utilisations thérapeutiques

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR